Severe sepsis
Disease1 paper1 finding
- Humans1
Associations
1SGLT2 inhibitors
downin humans1HR 0.81Low certainty
1 study
SGLT2 inhibitors
downin humans1HR 0.81Low certainty
SGLT2 inhibitors lower the risk of severe sepsis in humans (HR, 0.81; 95% CI, 0.73-0.90).
Humanspatients with chronic kidney disease and type 2 diabetes1 year
Sodium-glucose cotransporter-2 inhibitors, severe sepsis, and infection-related outcomes in patients with chronic kidney disease and type 2 diabetes · Kidney research and clinical practice · 8 Sep 2026
Trial sponsors
SepNet - Critical Care Trials Group
1 trialPhase 3600 people
Universitaire Ziekenhuizen KU Leuven
1 trialPhase 3301 people
Aragon Institute of Health Sciences
1 trialPhase 3110 people
Community Medical Center, Toms River, NJ
1 trialPhase 2140 people
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
1 trialPhase 220 people
1 trialPhase 22 people
Children's Hospital Medical Center, Cincinnati
1 trialPhase 1/212 people
1 trialPhase 155 people